61 related articles for article (PubMed ID: 31937861)
1. Carbon-based glyco-nanoplatforms: towards the next generation of glycan-based multivalent probes.
Ramos-Soriano J; Ghirardello M; Galan MC
Chem Soc Rev; 2022 Dec; 51(24):9960-9985. PubMed ID: 36416290
[TBL] [Abstract][Full Text] [Related]
2.
Serda M; Malarz K; Korzuch J; Szubka M; Zubko M; Musioł R
ACS Biomater Sci Eng; 2022 Aug; 8(8):3450-3462. PubMed ID: 35856645
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and applications of [60]fullerene nanoconjugate with 5-aminolevulinic acid and its glycoconjugate as drug delivery vehicles.
Serda M; Gawecki R; Dulski M; Sajewicz M; Talik E; Szubka M; Zubko M; Malarz K; Mrozek-Wilczkiewicz A; Musioł R
RSC Adv; 2022 Feb; 12(11):6377-6388. PubMed ID: 35424628
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Activity and Potential Mechanism of Novel Fullerene Derivative Nanoparticles.
Ye L; Kollie L; Liu X; Guo W; Ying X; Zhu J; Yang S; Yu M
Molecules; 2021 May; 26(11):. PubMed ID: 34071369
[TBL] [Abstract][Full Text] [Related]
5. Novel Benzenesulfonate Scaffolds with a High Anticancer Activity and G2/M Cell Cycle Arrest.
Malarz K; Mularski J; Kuczak M; Mrozek-Wilczkiewicz A; Musiol R
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918637
[TBL] [Abstract][Full Text] [Related]
6. Interactions of a Water-Soluble Glycofullerene with Glucose Transporter 1. Analysis of the Cellular Effects on a Pancreatic Tumor Model.
Barańska E; Wiecheć-Cudak O; Rak M; Bienia A; Mrozek-Wilczkiewicz A; Krzykawska-Serda M; Serda M
Nanomaterials (Basel); 2021 Feb; 11(2):. PubMed ID: 33670509
[TBL] [Abstract][Full Text] [Related]
7. Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.
Creeden JF; Alganem K; Imami AS; Henkel ND; Brunicardi FC; Liu SH; Shukla R; Tomar T; Naji F; McCullumsmith RE
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233470
[TBL] [Abstract][Full Text] [Related]
8. The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors.
Malarz K; Mularski J; Pacholczyk M; Musiol R
Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32110969
[TBL] [Abstract][Full Text] [Related]
9. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
10. A Fast and Clean BTK Inhibitor.
Gabizon R; London N
J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
[TBL] [Abstract][Full Text] [Related]
11. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment.
Serda M; Malarz K; Mrozek-Wilczkiewicz A; Wojtyniak M; Musioł R; Curley SA
Sci Rep; 2020 Jan; 10(1):260. PubMed ID: 31937861
[TBL] [Abstract][Full Text] [Related]
12. Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor.
Malarz K; Korzuch J; Marforio TD; Balin K; Calvaresi M; Mrozek-Wilczkiewicz A; Musiol R; Serda M
Int J Nanomedicine; 2023; 18():1709-1724. PubMed ID: 37025922
[TBL] [Abstract][Full Text] [Related]
13. Fyn kinase in brain diseases and cancer: the search for inhibitors.
Schenone S; Brullo C; Musumeci F; Biava M; Falchi F; Botta M
Curr Med Chem; 2011; 18(19):2921-42. PubMed ID: 21651487
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G
Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
